Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (GB:0QOK)
LSE:0QOK
0QOK Stock Chart & Stats
CHF313.62
CHF8.64(3.34%)
At close: 4:00 PM EST
CHF313.62
CHF8.64(3.34%)
Day’s Range― - ―
52-Week RangeCHF221.30 - CHF377.00
Previous CloseN/A
Volume341.09K
Average Volume (3M)433.97K
Market Cap
$240.33B
Enterprise ValueCHF268.12B
Total Cash (Recent Filing)$15.48B
Total Debt (Recent Filing)$31.64B
Price to Earnings (P/E)11.9
Beta0.88
Next Earnings
Jul 23, 2026EPS Estimate
10.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.38
Shares Outstanding702,562,700
10 Day Avg. Volume520,275
30 Day Avg. Volume433,969
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.73
Price to Sales (P/S)4.25
P/FCF Ratio18.55
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue4.36
Enterprise Value/Gross Profit5.93
Enterprise Value/Ebitda11.83
Forecast
1Y Price Target
$350.31Price Target Upside11.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)20.11
Revenue Forecast (FY)$62.78B
Bulls Say, Bears Say
Bulls Say
Adjuvant Breast Cancer Market Opportunity For GiredestrantGiredestrant targets most hormone receptor–positive, HER2‑negative breast cancer patients and appears better tolerated than current standards, and a regulator‑permitted label allowing switches from aromatase inhibitor therapy would expand the eligible adjuvant patient pool.
Clinical Trial Efficacy In Relapsing Multiple SclerosisPhase 3 data show fenebrutinib produced a substantial reduction in relapse activity versus an active comparator, with secondary endpoints indicating fewer brain lesions and favorable trends on progression, supporting stronger treatment positioning in relapsing multiple sclerosis.
Diagnostics Platform And Technology-driven GrowthLaunch of a high-speed sequencing platform, a proprietary sensor chip and an automated mass spectrometry workflow could create high barriers to entry and drive meaningful, durable revenue growth in the diagnostics division to help offset pharmaceutical revenue pressures.
Bears Say
Evidence And Adoption Risk For Combination TherapyWidespread use of giredestrant in combination with CDK4/6 inhibitors may depend on definitive randomized studies, creating an evidence gap that could slow physician adoption and payer coverage despite tolerability advantages.
Regulatory And Approval UncertaintySafety signals and unresolved toxicity questions increase uncertainty around regulatory approval and labeling for fenebrutinib, which could constrain commercial potential and prompt cautious analyst assessments.
Severe Safety Signals For FenebrutinibReports of multiple fatal cases in the fenebrutinib treatment arm alongside elevated liver enzymes and events meeting biochemical Hy’s law raise material safety concerns that could limit clinical use and investor confidence.
Roche Holding AG News
0QOK FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest share price was CHF221.30 and its highest was CHF377.00 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is $240.33B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jul 23, 2026 which is in 124 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jan 29, 2026. The company reported CHF8.375 earnings per share for the quarter, missing the consensus estimate of CHF8.515 by -CHF0.14.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG does not currently pay dividends.
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 10.76.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of CHF8.375 in its last earnings report, missing expectations of CHF8.515. Following the earnings report the stock price went up 1.883%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in GB:0QOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
0QOK Company Deck
0QOK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted strong growth in pharmaceutical sales and robust pipeline development, particularly in oncology and neurology. However, challenges in the Diagnostics segment due to China's pricing reforms and mixed clinical trial results tempered the positive outlook. Additionally, regulatory setbacks and geopolitical uncertainties added caution.View all GB:0QOK earnings summaries0QOK Stock 12 Month Forecast
Average Price Target
CHF350.31
▲(11.70% Upside)
Technical Analysis
Options Prices
Currently, No data available
---